Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mural Oncology plc - Ordinary Shares (NQ:MURA)

2.090 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mural Oncology plc - Ordinary Shares

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Mural Oncology, Inc.
Via GlobeNewswire
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Participate in Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology to Present at Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
MURA Stock Earnings: Mural Oncology Beats EPS for Q2 2024
MURA stock results show that Mural Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
From Mural Oncology, Inc.
Via GlobeNewswire
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
From Mural Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.